SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

January 23, 2024

https://www.globenewswire.com/news-release/2024/01/23/2814588/0/en/SAB-Biotherapeutics-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html

SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) on January 23, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.

Read more at globenewswire.com

Related news for (SABS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.